logo
Fermilab: Muon g-2 announces most precise measurement of the magnetic anomaly of the muon

Fermilab: Muon g-2 announces most precise measurement of the magnetic anomaly of the muon

Yahoo04-06-2025
The third and final result, based on the last three years of data, is in perfect agreement with the experiment's previous results, further solidifying the experimental world average. This long-awaited value will be the world's most precise measurement of the muon magnetic anomaly for many years to come.
Muon g-2 ring
Results plot graph
Batavia, Ill., June 04, 2025 (GLOBE NEWSWIRE) -- Scientists working on the Muon g-2 experiment, hosted by the U.S. Department of Energy's Fermi National Accelerator Laboratory, have released their third and final measurement of the muon magnetic anomaly. This value is related to g-2, the experiment's namesake measurement. The final result agrees with their published results from 2021 and 2023 but with a much better precision of 127 parts-per-billion, surpassing the original experimental design goal of 140 parts-per-billion.
'The anomalous magnetic moment, or g–2, of the muon is important because it provides a sensitive test of the Standard Model of particle physics. This is an exciting result and it is great to see an experiment come to a definitive end with a precision measurement,' said Regina Rameika, the U.S. Department of Energy's Associate Director for the Office of High Energy Physics.
This long-awaited result is a tremendous achievement of precision and will remain the world's most precise measurement of the muon magnetic anomaly for many years to come. Despite recent challenges with the theoretical predictions that reduce evidence of new physics from muon g-2, this result provides a stringent benchmark for proposed extensions of the Standard Model of particle physics.
'This is a very exciting moment because we not only achieved our goals but exceeded them, which is not very easy for these precision measurements,' said Peter Winter, a physicist at Argonne National Laboratory and co-spokesperson for the Muon g-2 collaboration. 'With the support of the funding agencies and the host lab, Fermilab, it has been very successful overall, as we reached or surpassed pretty much all the items that we were aiming for.'
'For over a century, g-2 has been teaching us a lot about the nature of nature,' said Lawrence Gibbons, professor at Cornell University and analysis co-coordinator for this result. 'It's exciting to add a precise measurement that I think will stand for a long time.'
The Muon g-2 (pronounced 'gee minus two') experiment looks at the wobble of a fundamental particle called the muon. Muons are similar to electrons but about 200 times more massive; like electrons, muons have a quantum mechanical property called spin that can be interpreted as a tiny internal magnet. In the presence of an external magnetic field, the internal magnet will wobble — or precess — like the axis of a spinning top.
The precession speed in a magnetic field depends on properties of the muon described by a number called the g-factor. Theoretical physicists calculate the g-factor based on the current knowledge of how the universe works at a fundamental level, which is contained in the Standard Model of particle physics.
Nearly 100 years ago, the value of g was predicted to be 2. But experimental measurements soon showed g to be slightly different from 2 by a quantity known as the magnetic anomaly of the muon, aμ, calculated with (g-2)/2. The Muon g-2 experiment gets its name from this relation.
The muon magnetic anomaly encodes the effects of all Standard Model particles, and theoretical physicists can calculate these contributions to an incredible precision. But previous measurements taken at Brookhaven National Laboratory in the late 1990s and early 2000s showed a possible discrepancy with the theoretical calculation at that time.
When experiment doesn't align with theory, it could indicate new physics. Specifically, physicists wondered if this discrepancy could be caused by as-yet undiscovered particles pulling at the muon's precession.
So physicists decided to upgrade the Muon g-2 experiment to make a more precise measurement. In 2013, Brookhaven's magnetic storage ring was transported from Long Island, New York, to Fermilab in Batavia, Illinois. After years of significant upgrades and improvements, the Fermilab Muon g-2 experiment started up on May 31, 2017.
In parallel, an international collaboration of theorists formed the Muon g-2 Theory Initiative to improve the theoretical calculation. In 2020, the Theory Initiative published an updated, more precise Standard Model value based on a technique that uses input data from other experiments.
The discrepancy with the result from that technique continued to grow in 2021 when Fermilab announced its first experimental result, confirming the Brookhaven result with a slightly improved precision. At the same time, a new theoretical prediction came out based on a second technique that heavily relies on computational power. This new number was closer to the experimental measurement, narrowing the discrepancy.
Recently, the Theory Initiative published a new prediction combining the results of several groups that used the new computational technique. This result remains closer to the experimental measurement, dampening the possibility of new physics. However, the theoretical effort will continue to work to understand the discrepancy between the data-driven and computational approaches.
The latest experimental value of the magnetic moment of the muon from the Fermilab experiment is:
aμ = (g-2)/2 (muon, experiment) = 0.001 165 920 705 +- 0.000 000 000 114(stat.) +- 0.000 000 000 091(syst.)
This final measurement is based on the analysis of the last three years of data, taken between 2021 and 2023, combined with the previously published datasets. This more than tripled the size of the dataset used for their second result in 2023, and it enabled the collaboration to finally achieve their precision goal proposed in 2012.
It also represents an analysis of the experiment's best-quality data. Toward the end of their second data-taking run, the Muon g-2 collaboration finished tweaks and enhancements to the experiment that improved the quality of the muon beam and reduced uncertainties.
The Muon g-2 collaboration describes the result in a paper that they submitted today to Physical Review Letters.
'As it has been for decades, the magnetic moment of the muon continues to be a stringent benchmark of the Standard Model,' said Simon Corrodi, assistant physicist at Argonne National Laboratory and analysis co-coordinator. 'The new experimental result sheds new light on this fundamental theory and will set the benchmark for any new theoretical calculation to come.'
A future experiment at the Japan Proton Accelerator Research Complex will likely make another measurement of the muon magnetic anomaly in the early 2030s, but, initially, they won't achieve the same precision as Fermilab.
Meanwhile, the Theory Initiative will continue working to resolve the inconsistency between their two theoretical predictions.
The Muon g-2 collaboration is made up of nearly 176 scientists from 34 institutions in seven countries. Marco Incagli, a physicist with the Italian National Institute for Nuclear Physics at Pisa and co-spokesperson for Muon g-2, emphasized that the internationality of the collaboration was key to the success of the experiment.
Unusually, the scientists also represent a variety of physics areas. 'This experiment is quite peculiar because it has very different ingredients in it,' said Incagli. 'It is really done by a collaboration among communities that normally work on different experiments.'
Unlike other high-energy physics experiments, Muon g-2 needed more than just high-energy physicists; the collaboration is also composed of accelerator physicists, atomic physicists and nuclear physicists. 'It was very valuable to see that, when we had all these different experts come together, we could solve items that probably one group could not have done alone,' said Incagli.
While the experiment's main analysis has come to an end, there is more to be mined from the six years of Muon g-2 data. In the future, the collaboration will produce measurements of a property of the muon called the electric dipole moment as well as tests of a fundamental property of physical laws known as charge, parity, and time-reversal symmetry.
'It's a really beautiful experiment,' said Gibbons. 'The data that comes out is really exquisite. It's been a privilege to have access to this data and analyze it.'
'Of course, it's sad to end such an endeavor because it's been a large part of many of our collaborators' lives,' said Winter, who has been part of the collaboration since 2011. 'But we also want to move to the next physics that's out there, to do our best to advance the field in other areas.
'I think it will be a textbook experiment that will be a long-lasting reference for many future decades to come,' Winter added.
Fermi National Accelerator Laboratory is America's premier national laboratory for particle physics and accelerator research. Fermi Forward Discovery Group manages Fermilab for the U.S. Department of Energy Office of Science. Visit Fermilab's website at www.fnal.gov and follow us on social media.
Attachments
Muon g-2 ring
Results plot graph
CONTACT: Tracy Marc Fermilab 2242907803 TRACYM@FNAL.GOVSign in to access your portfolio
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GENIUS Act: The Catalyst for Trillions in Real-World Asset Tokenization with Deal Box and OroBit
GENIUS Act: The Catalyst for Trillions in Real-World Asset Tokenization with Deal Box and OroBit

Business Upturn

time4 hours ago

  • Business Upturn

GENIUS Act: The Catalyst for Trillions in Real-World Asset Tokenization with Deal Box and OroBit

San Diego, CA , Aug. 04, 2025 (GLOBE NEWSWIRE) — The passage of the landmark GENIUS Act marks a defining moment for the digital asset industry, further opening the door for mainstream adoption of real-world asset (RWA) tokenization, an industry expected to surpass $16 trillion this decade. Positioned at the heart of this financial evolution are fintech pioneer Thomas Carter's Deal Box and blockchain infrastructure innovator OroBit—two firms uniquely prepared to harness these converging opportunities. The GENIUS Act provides explicit regulatory guidelines for stablecoins and digital assets, clarifying critical elements such as reserve requirements (mandating 100% reserves in USD or short-term Treasuries), monthly audits, AML compliance, and dual federal and state licensing oversight. These clear guidelines remove major uncertainties that have long constrained institutional participation, signaling an era of greater investor confidence and market stability. This regulatory clarity arrives during an unprecedented uptick in institutional interest in cryptocurrency markets, notably driven by recent Bitcoin ETF approvals and increasing investment from banks and asset managers. The crypto market capitalization has surged past $4 trillion, reflecting robust, ongoing confidence from institutional treasuries. Thomas Carter, CEO and founder of Deal Box, emphasized the strategic importance of this regulatory development: 'The GENIUS Act couldn't be better timed. The clarity and legitimacy it provides aligns perfectly with growing institutional confidence in digital assets. This convergence creates precisely the environment we've anticipated, enabling Deal Box and our partners at OroBit to rapidly scale tokenization solutions, especially in private equity and traditionally illiquid markets.' Since its inception in 2016, Deal Box has actively championed the tokenization of private equity and alternative assets, offering investors unprecedented access, transparency, and liquidity. Deal Box is also at the forefront of AI technology, partnering with Wild Mouse, an Australian enterprise software company, which has developed a globally unique platform designed to ingest, analyze, and act on unstructured data at scale, offering transformative potential for companies like OroBit. OroBit complements this vision with their sophisticated Smart Contract Layer (SCL), a robust blockchain protocol built on Bitcoin, securely automating tokenization, ownership management, and compliance processes, providing infrastructure for mainstream adoption. By leveraging Bitcoin—the largest and most secure blockchain—OroBit is strategically positioned to capture substantial value as the Bitcoin network itself experiences historic growth and adoption. Warwick Powell, Chairman of OroBit, highlighted the transformative impact of this legislation and strategic alignment: 'The GENIUS Act directly validates the infrastructure we've developed, clearing the path for institutional-grade adoption at a scale previously unimaginable. Alongside Deal Box, we're positioned to become the new standard-bearer for secure, compliant, and efficient tokenized financial products.' The unified ecosystem they have crafted, powered by an enterprise-grade AI platform, is redefining how private equity, real estate, art, and other high-value assets are owned, traded, and managed globally. The long-anticipated tokenization revolution is now underway. About Deal Box Deal Box is venture capital that fits your life. We bring institutional clarity to tokenized and traditional assets through credible AI structuring, Bitcoin-first token design, and packaging built for investor diligence. Structured for issuer-led offerings under Rule 506(c), Deal Box does not act as a broker-dealer or placement agent and receives no compensation tied to capital raised. contact: [email protected] About OroBit OroBit delivers secure, scalable Bitcoin Layer-2 solutions, enabling sophisticated smart-contract capabilities specifically tailored to institutional and private market asset tokenization. See for more information contact [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Business Upturn

time4 hours ago

  • Business Upturn

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Pacific Green Signs Commitment Agreement With ZEN Energy for BESS Offtake in Australia for 1.5GWh
Pacific Green Signs Commitment Agreement With ZEN Energy for BESS Offtake in Australia for 1.5GWh

Business Upturn

time4 hours ago

  • Business Upturn

Pacific Green Signs Commitment Agreement With ZEN Energy for BESS Offtake in Australia for 1.5GWh

By GlobeNewswire Published on August 5, 2025, 03:30 IST Sydney, Aug. 05, 2025 (GLOBE NEWSWIRE) — – Pacific Green is pleased to announce that its battery energy storage business in Australia has entered into a commitment agreement with ZEN Energy ('ZEN') for 10-year tolling arrangements across three Battery Energy Storage System (BESS) projects located in Victoria, New South Wales, and Queensland totaling 1.5GWh of storage capacity. This milestone marks a pivotal step in Pacific Green's transition to its next phase of growth, significantly accelerating the route to market for its Australian project portfolio of 7GWh. Scott Poulter, Pacific Green's Group CEO, commented: 'Following our initial offtake agreement of 500MWh for Limestone Coast North in South Australia, we are delighted to enter into a strategic framework for a further 1.5GWh. This framework agreement helps Pacific Green underwrite a significant part of the our portfolio of developments in Victoria, New South Wales and Queensland, and enables Pacific Green to industrialize its project development processes.' Anthony Garnaut, CEO of ZEN, stated: 'ZEN and Pacific Green share a strategy that has storage at its heart. This next stage of ZEN's deepening partnership with Pacific Green enables us to support our growing book of sustainability-driven commercial and industrial customers, as well as smooth the volatility inherent in the energy transition, as we meet the 24/7 requirements of our customers.' Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store